Lonza Cologne GmbH

https://www.lonza.com

As a globally active leader in transfection technologies, amaxa is dedicated to enhancing the speed and quality of basic and pharmaceutical research in gene transfer, gene silencing, and gene-based medicine. amaxa’s Nucleofector® Technology provides the first efficient non-viral method for the transfer of DNA or siRNA directly into the nucleus of primary cells and hard-to-transfect cell lines. Based on electroporation, Nucleofection® utilizes novel and unique electrical parameters generated by a special Nucleofector® Device. These are combined with different, cell type specific reagents. amaxa is the worldwide market leader in the segment of primary cell transfection. Founded in 1998, amaxa is located in Cologne, Germany, and in Gaithersburg, MD, USA, and currently employs 160 people. The company's research team is one of the largest R&D groups working on non-viral gene transfer. *

	Start	2008-07-03 renamed date ca
	Group	Lonza (Group)
	Predecessor	amaxa AG
	Industry	gene transfer technology
	Industry 2	Nucleofector® technology

	Region	Köln (Cologne)
	Country	Germany
	Street	1 Nattermannallee
	City	50829 Köln
	Tel	+49-221-99199-0
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2010-01-01)

		* Document for »About Section«:

		Record changed: 2023-12-30